EGFR and nasopharyngeal carcinoma: Given the finding of the high prevalence of EGFR overexpression, a phase II study of cetuximab (Erbitux, C-225) in combination with carboplatin for patients with metastatic or recurrent NPC was undertaken (Chan et al, 2003).